logo
Cast AI unveils Database Optimizer to boost cloud efficiency

Cast AI unveils Database Optimizer to boost cloud efficiency

Techday NZa day ago

Cast AI has announced the launch of its Database Optimizer (DBO), an autonomous caching solution designed to improve performance and efficiency for cloud-hosted databases.
The Database Optimizer offers a fully automated, plug-and-play caching layer that does not require application changes or manual intervention, according to Cast AI. The solution is aimed at simplifying database operations, specifically for DevOps teams, platform engineers and cloud database administrators who often face challenges with traditional, labour-intensive caching solutions.
Dekel Shavit, Senior Director of Cloud Engineering at Akamai, commented on the product's approach, stating, "Autonomous caching is one of the most effective ways to optimize read-heavy workloads, and Cast AI's approach is brilliantly executed. DBO removes the need for manual tuning while delivering real-time performance gains and cost reductions. It's a strong addition to the Cast AI platform."
According to Cast AI, the DBO agent automatically analyses data queries to detect repeat patterns and delivers instant cached responses, leading to a substantial reduction in load on primary databases. The company reports that this can result in a reduction of up to 90% of customer database hits, allowing organisations to downscale database resources and eliminate the need for read replicas. All of these optimisations can be achieved without code changes, manual cache management or other engineering overhead.
Key features highlighted by the company include simplified database optimisation through actionable insights and turnkey deployment, a claimed tenfold performance improvement due to near-instant data delivery, and the capability to automate cache management in a no-code fashion.
Julius á Rógvi Biskopstø, Chief Technology Officer and Co-founder at Flowcore, described the practical benefits observed from adopting Cast AI's DBO, saying, "One of the toughest challenges with database caching—especially in distributed systems like ours—is cache invalidation. But with Cast AI's DBO, it just works right out of the box. Our workloads are highly cacheable because we separate reads from writes, so integrating with the write channels was straightforward—even in clustering mode."
Biskopstø continued, "We're now seeing cache hit rates of 80–90%, which is outstanding. On I/O-bound servers, cutting database hits by 90% has a huge impact—it saves money and significantly improves performance. Our services were already pretty fast, but DBO shaved off an additional 100 milliseconds, which makes a noticeable difference. If you're thinking about adding a cache, DBO is an easy choice."
Laurent Gil, Co-founder and President at Cast AI, stated that DBO is designed to make database operations more efficient and cost-effective. Gil said, "Databases are one of the most expensive components in the cloud. It was a natural addition to our Application Performance Automation platform. Our DBO agent increases performance and reduces cost by caching any queries for which it detects a repeat pattern., DBO radically simplifies caching, slashes expenses, and requires no changes to how your apps are built. APA is the future of autonomous computing —high performance, zero overhead."
The Database Optimizer is positioned by Cast AI as part of its broader Application Performance Automation platform, which leverages machine learning algorithms to automate cloud resource optimisation, cost management and performance enhancement.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Little-known site sees Marc Jacobs' 'perfect summer perfume' slashed to £33
Little-known site sees Marc Jacobs' 'perfect summer perfume' slashed to £33

Daily Mirror

time3 minutes ago

  • Daily Mirror

Little-known site sees Marc Jacobs' 'perfect summer perfume' slashed to £33

If you've been looking for a new signature scent, Marc Jacobs' Dot, which shoppers say is perfect for summer, is now £33 instead of £99 thanks to this hidden gem savings site Purchasing a new fragrance requires a lot of thought and can be a real investment, especially if you're looking at designer fashion house perfumes that come with near-£100 price tags, if not even more. Luckily, if you are on the lookout for a signature scent, little-known savings site, Boop Beauty, has just slashed Marc Jacobs' Dot Eau de Parfum from £99 to £32.99 - that's a huge 67% discount! Dot is an iconic feel-good fragrance featuring notes of red berries, dragonfruit, and honeysuckle, which add a sweet, refreshing, summer touch. The soft floral notes of jasmine and orange blossom, with a hint of coconut water, give it a light, tropical feel that makes it perfect for summertime. Inspired by Marc Jacobs' iconic polka dots, the bottle features a gorgeous red-and-black spotted design with oversized butterfly wings for a playful touch. Not to mention, right on trend for this season. The gold coil around the neck adds a touch of luxe, making it a standout on any dressing table or shelf. Whether you're gifting someone special or treating yourself, Dot is the kind of perfume that feels like summer in both scent and style. Boop is not the only place where this summery scent is discounted. Currently, Boots is offering a huge 50% off, too, bringing the price down from £99 to £49. And if you're looking for further wallet-friendly fragrances, . Jimmy Choo's popular Flash Eau de Parfum, praised by shoppers for its long-lasting wear and feminine smell, is currently available for less than £25 in a limited-time flash sale on LookFantastic. Hundreds of shopper reviews praise Marc Jacobs Dot for its fruity and fresh scent. One happy shopper wrote, "It's a lovely, fresh summery fragrance that makes me feel warm and relaxed." A second added: "I have liked other Marc Jacob's so decided to give this one a try and I am certainly not disappointed I love the top on the bottle and the perfume is not like anything I've bought before, really like it." The only criticisms came from a few shoppers who claimed Dot does not last quite as long on the skin as some of Marc Jacobs' other fragrances, like his cult-favourite Daisy perfumes.

Three-drug therapy helps women with aggressive breast cancer live longer
Three-drug therapy helps women with aggressive breast cancer live longer

Glasgow Times

time3 minutes ago

  • Glasgow Times

Three-drug therapy helps women with aggressive breast cancer live longer

The treatment could also delay the need for gruelling chemotherapy, according to a trial. Researchers are hopeful the combination could become the 'new go-to option' for women with PIK3CA-mutated hormone receptor positive (HR+) human epidermal growth factor receptor 2 negative (HER2-) breast cancer. This mutation in the PIK3CA gene causes cells to divide and replicate uncontrollably. The final results from the INAVO120 study, led by experts at The Institute of Cancer Research, London, and the Royal Marsden NHS Foundation Trust, have been published in the New England Journal of Medicine and presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago. The trial included 325 patients from across 28 countries. More than half had metastatic breast cancer that had spread to three or more organs and the majority had already had chemotherapy. Researchers used a blood test known as a liquid biopsy, which detects tumour DNA in the blood, to test for the PIK3CA mutation. Of the total, 161 were given a three-drug combination comprising two targeted drugs – palbociclib, a type of cancer growth blocker, and a new drug called inavolisib, which blocks the activity of the PI3K protein – as well as the hormone therapy fulvestrant. The placebo group, which included 164 patients, was given a dummy pill plus palbociclib and fulvestrant. The study found the median overall survival in the inavolisib group was 34 months, compared with 27 months in the placebo group. The three-drug therapy also delayed disease progression by 17.2 months, compared with 7.3 months in the placebo group, with patients also able to delay chemotherapy treatment by almost two years longer. The latest results come after previous analysis of the study, published in October, showed the three-drug therapy delayed disease progression by an average of 15 months compared with 7.3 months in the placebo group. Lead author Nick Turner, a professor of molecular oncology at The Institute of Cancer Research, London, and consultant medical oncologist at The Royal Marsden NHS Foundation Trust, said: 'The key findings from this study showed that the inavolisib-based therapy not only helped patients live longer but it more than doubled the time before their cancer progressed or worsened. 'It also gave them more time before needing subsequent chemotherapy which we know is something that patients really fear and want to delay for as long as possible. 'These results give us confidence that this treatment could become the new go-to option for patients who have HR+, HER2- breast cancer with a PIK3CA mutation, as it has shown significant improvements in both survival and quality of life.' It is estimated that about 55,000 women are diagnosed with breast cancer in the UK every year, some 70% of whom will have HR+, HER2- breast cancer. PIK3CA mutations are found in 35-40% of HR+ breast cancers. The three-drug therapy of inavolisib, palbociclib and fulvestrant is not approved in the UK. However, the combination of palbociclib and fulvestrant has been available as an option for patients with certain types of breast cancer on the NHS since 2022. Prof Kristian Helin, chief executive of The Institute of Cancer Research, London, added: 'If we are to continue improving cancer survival rates, we need to tackle treatment resistance head on. 'This research demonstrates how this triple combination approach effectively shuts down cancer's escape routes, giving people with metastatic breast cancer the opportunity to live well for longer. 'One of the challenges with combination therapies is ensuring the right drug dosages and understanding their individual effects. 'It is extremely encouraging that this study not only demonstrates the effectiveness of this approach but also shows that the therapy was generally well tolerated by patients.' Reacting to the findings, Dr Simon Vincent, director of research, support and influencing at Breast Cancer Now, said: 'This is a significant breakthrough and we're proud that it builds on a series of discoveries that our funded scientists have been making at the Breast Cancer Now Toby Robins Research Centre at The Institute of Cancer Research, London, since it opened 25 years ago. 'We now hope to see this new combination therapy can be licensed by the MHRA (Medicines and Healthcare Products Regulatory Agency) and assessed by Nice (the National Institute for Health and Care Excellence) and the Scottish Medicine Council as soon as possible so that it can reach the NHS patients who could benefit from it.'

French Open stars tweak match slots to catch the Champions League final
French Open stars tweak match slots to catch the Champions League final

Business Standard

time4 minutes ago

  • Business Standard

French Open stars tweak match slots to catch the Champions League final

The French Open isn't the only sports event in Europe drawing attention from tennis players: The Champions League final will decide the continent's best soccer club, and one of the two teams involved Saturday night is Paris Saint-Germain, whose stadium is a couple of blocks from Roland-Garros. Count Novak Djokovic among those rooting for PSG against Italy's Inter Milan, and he hoped to be able to tune in on TV to watch the big clash that'll be held in Munich, Germany. So Djokovic made that preference known to the people in charge of arranging the program at the clay-court Grand Slam tournament he's won three times a common practice, especially among the sport's elite. They often ask to be scheduled at a certain time. Or to avoid a certain time. I will definitely watch it if I'm not playing (in the) night session. Yeah, that will be nice, Djokovic said with a big smile. FYI, Roland-Garros schedule. Hint, hint. Except his plea went unheeded: When Saturday's order of play was released Friday, 24-time major champion Djokovic's third-round match against Filip Misolic was the one picked for under the lights at Court Philippe-Chatrier due to begin at 8:15 p.m. local time, 45 minutes before Inter Milan vs. PSG starts. Others who begged off from competing at that hour got their wish. Although one, Arthur Fils, the 14th-seeded Frenchman who grew up near Paris and is a big PSG fan, wound up pulling out of the tournament because of a back injury after being placed in an afternoon match against No. 17 Andrey Rublev. We have many requests from players every day, tournament director Amlie Mauresmo said. There's no fixed rule. We try to accommodate everyone as much as possible. That includes requests from players, broadcasters and spectators. ... It's a real puzzle, I won't lie. Coco Gauff said she doesn't often ask for a certain time slot, but when she does, it's usually related to competing in singles and doubles on the same day (the American won the French Open doubles title last year but isn't playing doubles this time). The 2023 U.S. Open champion, who is currently No. 2 in singles, has noticed that events tend to listen more to elite players than others. If you're ranked a little bit higher, they'll hear more of your input, for sure, Gauff said. To be honest, I think it's rightfully deserved. I feel like if you do well on tour, win so many tournaments, you should have a little bit more priority when it comes to that. Except even the very best of the best don't always have success with these sorts of things. Madison Keys, who was the U.S. Open runner-up in 2017 and won the Australian Open in January, knows what it's like to be ignored. Sometimes the request goes (in), they write it down, and they say, OK,' but then don't do anything about it, Keys said. I really think that it's just kind of up to what the tournament wants, what TV wants, things like that, she added. Sometimes you kind of get what you ask for. And other times, you get the complete opposite. Just ask Djokovic. Whatever they schedule me, I have to accept, he said earlier this season. I think I earned my right to ... (communicate) with the tournament management, where I can express what I would like, depending on a given day, depending on the opponent.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store